Moleculin Biotech, Inc. (NASDAQ:MBRX) Stock Short Interest Drops 56.8%

Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) saw a significant decrease in short interest in the month of October. As of October 30th, there was short interest totaling 54,541 shares, a decrease of 56.8% from the October 15th total of 126,324 shares. Approximately 6.5% of the shares of the company are sold short. Based on an average daily volume of 67,646 shares, the short-interest ratio is presently 0.8 days.

Moleculin Biotech Price Performance

Shares of MBRX traded down $0.12 on Tuesday, reaching $7.01. The company’s stock had a trading volume of 11,024 shares, compared to its average volume of 32,954. The stock’s 50 day simple moving average is $9.80 and its two-hundred day simple moving average is $36.28. The stock has a market capitalization of $7.23 million, a P/E ratio of -0.05 and a beta of 2.11. Moleculin Biotech has a 12-month low of $3.23 and a 12-month high of $227.05.

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($9.59) EPS for the quarter, missing analysts’ consensus estimates of ($8.87) by ($0.72). Analysts expect that Moleculin Biotech will post -47.40 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. HC Wainwright decreased their target price on shares of Moleculin Biotech to $60.00 and set a “buy” rating for the company in a research note on Friday, August 28th. Wall Street Zen downgraded Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Moleculin Biotech currently has an average rating of “Hold” and a consensus price target of $60.00.

Check Out Our Latest Report on MBRX

Moleculin Biotech Company Profile

(Get Free Report)

Moleculin Biotech is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing treatments for cancer and other serious diseases. Its research centers on drug candidates intended to address cancers that can be difficult to treat with existing therapies. The company’s pipeline includes Annamycin, an investigational anthracycline being studied for acute myeloid leukemia and soft-tissue sarcoma that has spread to the lungs. Moleculin has described Annamycin as designed to avoid some limitations associated with older anthracyclines, including heart-related toxicity.

See Also

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.